Yunnan Huarui Biological Pharmaceutical

Yunnan Huarui Biological Pharmaceutical is a Chinese biopharmaceutical company specializing in the research, development, and large-scale production of plasma-derived therapies. Founded in 2021 and headquartered in the Kunming High-tech Zone, the company is constructing a major blood products production base with a planned annual plasma processing capacity of 1,200 tons. Its core product portfolio includes Human Albumin, Intravenous Human Immunoglobulin (IVIG), and Hepatitis B Human Immunoglobulin, aimed at treating conditions such as hypoproteinemia and immunodeficiencies. Led by industry veterans with experience from major Chinese blood product firms like Hualan Bio, the company is positioned as a significant player in Yunnan's growing life sciences sector.